ATE163012T1 - N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel - Google Patents

N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel

Info

Publication number
ATE163012T1
ATE163012T1 AT90116826T AT90116826T ATE163012T1 AT E163012 T1 ATE163012 T1 AT E163012T1 AT 90116826 T AT90116826 T AT 90116826T AT 90116826 T AT90116826 T AT 90116826T AT E163012 T1 ATE163012 T1 AT E163012T1
Authority
AT
Austria
Prior art keywords
loweralkyl
hydrogen
pyrimidinamines
aryl
pyrimidindiamines
Prior art date
Application number
AT90116826T
Other languages
English (en)
Inventor
Richard Charles Effland
Joseph Thomas Klein
Larry Davis
Gordon Edward Olsen
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Application granted granted Critical
Publication of ATE163012T1 publication Critical patent/ATE163012T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
AT90116826T 1989-09-05 1990-09-01 N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel ATE163012T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/402,415 US4983608A (en) 1989-09-05 1989-09-05 N-substituted-4-pyrimidinamines and pyrimidinediamines

Publications (1)

Publication Number Publication Date
ATE163012T1 true ATE163012T1 (de) 1998-02-15

Family

ID=23591798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90116826T ATE163012T1 (de) 1989-09-05 1990-09-01 N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel

Country Status (18)

Country Link
US (1) US4983608A (de)
EP (1) EP0417584B1 (de)
JP (1) JPH07116181B2 (de)
KR (1) KR0162641B1 (de)
AT (1) ATE163012T1 (de)
AU (1) AU626450B2 (de)
CA (1) CA2024572C (de)
DE (1) DE69032020T2 (de)
DK (1) DK0417584T3 (de)
ES (1) ES2112830T3 (de)
FI (1) FI904327A7 (de)
GR (1) GR3026318T3 (de)
IE (1) IE903213A1 (de)
IL (1) IL95568A (de)
NO (1) NO903851L (de)
NZ (1) NZ235145A (de)
PT (1) PT95202B (de)
ZA (1) ZA907033B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155098A (en) * 1989-06-09 1992-10-13 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5319096A (en) * 1992-04-03 1994-06-07 Hoechst-Roussel Pharmaceuticals Inc. (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2230896A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
ZA989365B (en) 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
DE69932828T2 (de) 1998-08-29 2007-10-18 Astrazeneca Ab Pyrimidine verbindungen
DE69933680T2 (de) * 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ATE396978T1 (de) * 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
US6410726B1 (en) 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US7115617B2 (en) * 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005524672A (ja) * 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP2130541A3 (de) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Verfahren zur Behandlung oder Vorbeugung von Autoimmunerkrankungen mit 2,4-Pyrimidindiaminverbindungen
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2529611C (en) * 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
JP4886511B2 (ja) * 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
MXPA06013164A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2006028833A1 (en) * 2004-09-01 2006-03-16 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
ATE540035T1 (de) * 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20090099160A1 (en) * 2004-12-17 2009-04-16 David Andrews 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋキナーゼインヒビターおよびそれらの使用
CA2617170A1 (en) * 2005-07-30 2007-02-08 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
BRPI0616722A2 (pt) * 2005-09-30 2012-12-25 Astrazeneca Ab composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
KR20100015546A (ko) 2007-04-13 2010-02-12 사노피-아벤티스 Ｎ-아미노인돌의 전이 금속 촉매된 합성
GB2578973B (en) * 2015-04-17 2020-08-26 Univ Holy Ghost Duquesne Pyrrolopyrimidines as antitumor agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792562A (en) * 1985-12-04 1988-12-20 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing activity
US4752610A (en) * 1985-12-04 1988-06-21 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing properties
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
US4806554A (en) * 1988-01-11 1989-02-21 Hoechst-Roussel Pharmaceuticals, Inc. Pyrazol and indazolpyridinamines
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines

Also Published As

Publication number Publication date
DE69032020D1 (de) 1998-03-12
GR3026318T3 (en) 1998-06-30
FI904327A0 (fi) 1990-09-03
JPH0393784A (ja) 1991-04-18
NO903851L (no) 1991-03-06
EP0417584A2 (de) 1991-03-20
PT95202A (pt) 1991-05-22
ZA907033B (en) 1991-06-26
CA2024572A1 (en) 1991-03-06
PT95202B (pt) 1997-06-30
CA2024572C (en) 2000-09-26
DE69032020T2 (de) 1998-07-09
IL95568A (en) 1995-01-24
NO903851D0 (no) 1990-09-04
NZ235145A (en) 1992-12-23
AU6208990A (en) 1991-03-14
EP0417584A3 (en) 1992-02-26
US4983608A (en) 1991-01-08
IL95568A0 (en) 1991-06-30
AU626450B2 (en) 1992-07-30
JPH07116181B2 (ja) 1995-12-13
EP0417584B1 (de) 1998-02-04
KR0162641B1 (ko) 1998-12-01
IE903213A1 (en) 1991-03-13
ES2112830T3 (es) 1998-04-16
FI904327A7 (fi) 1991-03-06
KR910006277A (ko) 1991-04-29
DK0417584T3 (da) 1998-09-23

Similar Documents

Publication Publication Date Title
ATE163012T1 (de) N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel
ATE81123T1 (de) 3-(4(1-substituierte-4-piperazinyl)butyl>-4thiazolidinone, verfahren zu deren herstellung und ihre anwendung als arzneimittel.
DE3772905D1 (de) Alpha-alkyl-4-amino-3-chinolin-methanole und 1-(4-aralkylamino-3-chinolyl)alkanone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ES2132284T3 (es) Derivados de carbamato de 2-(piperidin-4-il, piridin-4-il y tetrahidropiridin-4-il)-benzofurano-7, su preparacion y su uso como inhibidores de acetilcolinesterasa.
DE69016530D1 (de) 1,3-Dihydro-1-(pyridinylamino)-2H-indol-2-one, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
DE69022294D1 (de) N-Heteroaryl-purin-6-amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
DE69028605D1 (de) Aminocarbonylcarbamate verwandt mit Physostigmin, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE138377T1 (de) N-(aryloxyalkyl)heteroaryl-8- azabicyclo(3.2.1>octan, zwischenverbindungen und verfahren zu deren herstellung und deren verwendung als arzneimittel
DE69011013D1 (de) 1-(Pyridinylamino)-2-pyrrolidinone, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel.
ATE66913T1 (de) Amidverbindungen, verfahren zu ihrer herstellung und zusammensetzung zur aktivierung gastromotorischer funktionen.
DE69016531D1 (de) 2,3-Dihydro-1-(pyridinylamino)-indole, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel.
DE68902386D1 (de) N-pyridinyl-9h-carbazol-9-amine, verfahren zu ihrer herstellung und ihre verwendung als medikamente.
DE68914600D1 (de) Kondensierte heterocyclische Derivate von 1,2,3,4-Tetrahydroacridin, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament.
DE69110219D1 (de) 3-(1H-Indazol-3-yl)-4-pyridiname, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
ATE44031T1 (de) Antihypertensive 1,2-benzisothiazol-piperidine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EELA Cancelled due to lapse of time